Wall Street Payday: 4 Banks Made A Killing From Monday's $20 Billion In Biotech Deals

Scott Olson/Getty Images Biotech mergers and acquisitions are off to a hot start in 2018. On Monday, French drugmaker Sanofi spent $11.6 billion to buy US hemophilia firm Bioverativ, and Celgene spent $9 billion on cancer specialist Juno Therapeutics. Investment banks stand to make as much as $185 million in fees for advising on the deals. Two major biotech acquisitions dropped on Monday: French drugmaker Sanofi spent $11.6 billion to buy US hemophilia firm Bioverativ, and Celgene spent $9 billion on cancer specialist Juno Therapeutics. The more than $20 billion in pharma mergers and acquisitions means a windfall of as much as $185 million in fees for four investment banks, with JPMorgan raking in the most from the deals.

 

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More Business News